Regulation & Policy
MHRA publishes 2026–2030 plan to widen patient involvement in regulation
The regulator says it will involve patients earlier, hear from a broader range of communities and explain how their input shapes decisions on medicines, medical devices and AI.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Patient and Public Involvement and Engagement Plan 2026–2030. It sets out how the agency intends to involve patients and the public more in the regulation of medicines and medical devices. The MHRA announced the plan on 5 November 2026.
According to the MHRA, the plan is a key part of its Strategy 2030 and builds on its Patient Involvement Strategy 2021–2025. It also responds to feedback calling for more inclusive participation and clearer information on how patient involvement shapes regulatory decisions.
The agency said it will involve people earlier, hear from a wider range of patient groups and communities, and explain how patients' experiences influence its work. Lived experience will inform decisions including the assessment of medicines' benefits and risks, safety reviews, regulatory policy and patient information. It will also feed into approaches for rare diseases, medical devices, future regulatory pathways, artificial intelligence (AI) and other emerging technologies.
Commitments in the plan
Under the plan, the MHRA will:
- strengthen feedback, monitoring and reporting so people can see how their contributions have influenced its work; - expand membership of its Patient and Public Community to better reflect the diversity of the UK population; - use deliberative engagement so patient and public perspectives shape how the benefits and risks of medicines are assessed; - involve patients and the public in making medicines information clearer and more accessible; - work with the National Institute for Health and Care Excellence (NICE) to reduce duplication in patient involvement evidence used for regulatory and health technology assessments.
The Patient and Public Community was established in October 2024 and brings together patients, patient organisations and charities. The MHRA's People and Public Engagement Committee will review progress on the plan. Its chair, Mercy Jeyasingham MBE, who is also an MHRA non-executive director, said the plan "combines ambition with practical and achievable commitments".
The agency pointed to its rare disease work as an example of existing involvement. A dedicated advisory group of 23 patient representatives has contributed to the MHRA's Rare Disease Consortium, helping identify priorities, inform draft guidance and spearhead medicines repurposing, according to the MHRA.
MHRA Chair Professor Anthony Harnden described the plan as an evolution in how the agency connects with and listens to patients and the public. Professor Henrietta Hughes OBE, Patient Safety Commissioner for England, and Karen Titchener, Patient Safety Commissioner for Scotland, both welcomed it.
The press release does not give delivery dates for individual commitments.
Why it matters
The plan could change how evidence on patient experience is gathered and presented to the regulator, which is relevant to manufacturers of medicines and medical devices, including AI products. The commitment to work with NICE to reduce duplication in patient involvement evidence could, if delivered, simplify preparation for regulatory and health technology assessments. The press release gives no delivery dates, so the practical effect on submissions remains to be seen.
Source: MHRA
Related stories

Regulation & Policy
MHRA grants conditional approval to triheptanoin for rare inherited fatty acid disorders

Regulation & Policy
MHRA extends Casgevy approval to children aged five and over with sickle cell disease and β-thalassaemia

Regulation & Policy
Government commits almost £140m to 14 urgent care schemes ahead of NHS winter